Enliven Therapeutics Files 8-K on Governance and Officer Changes
Ticker: ELVN · Form: 8-K · Filed: Jun 18, 2024 · CIK: 1672619
| Field | Detail |
|---|---|
| Company | Enliven Therapeutics, Inc. (ELVN) |
| Form Type | 8-K |
| Filed Date | Jun 18, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: governance, officer-changes, director-changes
TL;DR
Enliven Therapeutics 8-K: Board shakeup, officer appointments, and governance updates filed June 18.
AI Summary
Enliven Therapeutics, Inc. filed an 8-K on June 18, 2024, reporting on several key events. These include the departure of directors or certain officers, the election of directors, the appointment of certain officers, and updates to compensatory arrangements for certain officers. The filing also covers amendments to articles of incorporation or bylaws, changes in fiscal year, and the submission of matters to a vote of security holders. Additionally, it includes financial statements and exhibits.
Why It Matters
This filing indicates significant changes in Enliven Therapeutics' corporate governance and executive team, which could impact the company's strategic direction and operational management.
Risk Assessment
Risk Level: medium — Changes in directors, officers, and compensatory arrangements can signal internal shifts or strategic realignments that may carry inherent business risks.
Key Players & Entities
- Enliven Therapeutics, Inc. (company) — Registrant
- IMARA Inc. (company) — Former Company Name
FAQ
Who has departed from Enliven Therapeutics' board or officer positions?
The filing indicates the departure of directors or certain officers, but specific names are not detailed in the provided text.
Were new directors or officers appointed?
Yes, the filing reports on the election of directors and the appointment of certain officers.
Are there any changes to Enliven Therapeutics' bylaws or articles of incorporation?
Yes, the filing mentions amendments to articles of incorporation or bylaws.
What is the fiscal year end for Enliven Therapeutics?
The fiscal year end for Enliven Therapeutics is December 31.
When was Enliven Therapeutics previously known as?
Enliven Therapeutics was formerly known as IMARA Inc., with a name change date of April 19, 2016.
Filing Stats: 1,054 words · 4 min read · ~4 pages · Grade level 14.2 · Accepted 2024-06-18 17:12:01
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share ELVN The Nasdaq Global Se
Filing Documents
- d853800d8k.htm (8-K) — 43KB
- d853800dex31.htm (EX-3.1) — 6KB
- d853800dex101.htm (EX-10.1) — 66KB
- 0001193125-24-163507.txt ( ) — 263KB
- elvn-20240618.xsd (EX-101.SCH) — 3KB
- elvn-20240618_lab.xml (EX-101.LAB) — 18KB
- elvn-20240618_pre.xml (EX-101.PRE) — 11KB
- d853800d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 3.1 Certificate of Amendment to the Company's Restated Certificate of Incorporation, dated June 18, 2024 10.1 Amended and Restated 2020 Equity Incentive Plan 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Enliven Therapeutics, Inc. Date: June 18, 2024 By: /s/ Samuel Kintz Name: Samuel Kintz Title: President and Chief Executive Officer